
Taro announces appointment of new CEO
pharmafile | November 25, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Taro pharmaceutical, sun pharmaceutical
Taro Pharmaceutical announced that Uday Baldota will take up the position of CEO and will begin the role in early April of 2017. Mr. Baldota will arrive at Taro from his current position of executive vice president and chief financial officer of Sun Pharmaceutical. Mr. Baldota has been working within the pharmaceutical industry for over 20 years, predominantly working at Sun Pharmaceutical.
Mr. Dilip Shanghvi, Taro’s chairman of the board stated, “I am confident that Uday’s experience, vision and leadership, will enable Taro to continue its growth path and deliver superior stakeholder value.” Mr. Shanghvi continued, “I expect to announce, in the near future, the appointment of an Interim CEO to manage Taro’s business during the three month period from Kal Sundaram’s departure at the end of this year until Uday’s arrival in April 2017.”
Sun Pharmaceutical acquired a controlling stake in Taro Pharmaceutical back in 2010.
Related Content

Sun Pharma partners with ICGEB to develop dengue vaccine
Indian drug firm Sun Pharma is set to join forces with the International Centre for …

Sun Pharmaceuticals hit with recall of over 31 thousand bottles of anti-depressants
Sun Pharmaceuticals have been forced to recall 31,762 bottles of anti-depressants from the US market …
Sun Pharma to partner with ICGEB to develop novel Dengue treatment
Sun Pharmaceuticals (BSE: 85715) and the International Centre for Genetic Engineering and Biotechnology (ICGEB) are …






